Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Biosimilars Had a Huge Impact on Total Cost of Care, Says AON’s Christine Pfaff
September 23rd 2023In a few short years, biosimilars have driven down total cost of care in oncology through providing competition for expensive drugs, explained Christine Pfaff, RPh, senior regional director of operations, American Oncology Network (AON).
Read More
Study Highlights Association of COPD and CVDs, Need for Prevention and Management
September 22nd 2023Among adults 40 years and older with chronic obstructive pulmonary disease (COPD), there is a higher prevalence of cardiovascular diseases (CVDs) compared with a general population without COPD.
Read More
Switching Back to Originator From Biosimilar Infliximab Results in Higher Discontinue Rates
September 16th 2023One-fourth of patients who switched to an infliximab biosimilar retransitioned back to the originator, but they were more likely to subsequently discontinue treatment due to an unwanted response after switching back.
Read More
Regional Disparities Remain in Breast Reconstruction for Patients With Breast Cancer
September 15th 2023While regional variations were identified in rates of breast reconstruction, complications, and cost for patients with breast cancer, these differences did not seem to be associated with any implicit bias.
Read More
Laura Wingate: Biosimilars Can Improve Access to Treatment for Patients
September 3rd 2023Biosimilars can improve access to treatment for patients who might not have been able to access biologics previously, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Laura Wingate Discusses Patient Education for Biosimilar Switches vs New Starts, Interchangeability
August 15th 2023Greater attention needs to be on educating patients who are switching from a reference product they are successful on to a biosimilar than a patient who is starting a treatment with a biosimilar at the beginning of their disease journey, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults
August 3rd 2023Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
Read More
Laura Wingate: Education Makes Patients More Confident in Biosimilar Switches
August 3rd 2023There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Dr Haley Naik: Improved Medical Education Can Help Reduce Diagnostic Delays of HS
July 30th 2023Some populations face longer diagnostic delays for hidradenitis suppurativa (HS), but medical education can help improve knowledge of common dermatologic diseases and reduce delays in diagnosis, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
Read More
Laura Wingate on the Unique Situation of 7 Adalimumab Biosimilars Coming to Market at Once
July 24th 2023Despite having 8 adalimumab biosimilars on the market now, patients may only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More
Patients With Hidradenitis Suppurativa Face Many Barriers When Accessing Care, Says Dr Haley Naik
July 23rd 2023Some of the many barriers patients with hidradenitis suppurativa (HS) face include accessing knowledgeable providers, insurance coverage of treatment, and the way the health care system is set up, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.
Read More
Dr Emma Guttman-Yassky: Strong Real-World Results of Biologics, JAK Inhibitors in AD
July 16th 2023Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.
Read More
Patient Education Can Prevent Nocebo Effect With Adalimumab Biosimilars, Explains Laura Wingate
July 15th 2023As Humira biosimilars enter the market, patient education about biosimilars is crucial to prevent the nocebo effect when patients switch from the reference product, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Read More